Cantor Fitzgerald reiterates Dyne Therapeutics stock rating

Cantor Fitzgerald has reaffirmed its Overweight rating on Dyne Therapeutics (NASDAQ:DYN) after the company shared further one-year data from its Phase 1/2 ACHIEVE study. The biotechnology company, with a market capitalization of $3.05 billion, has seen its shares drop 17% year-to-date, reaching $16.21, although they have still increased 28% over the past year.

The study examines the effects of z-basivarsen on patients with DM1. Dyne presented these findings at recent WMS and AANEM meetings, and the drug is being assessed in a 71-patient registrational expansion trial, with results expected in Q1 2027. This trial measures video hand opening time at six months as its primary endpoint, potentially allowing for an accelerated approval filing in Q3 2027.

According to InvestingPro, Dyne Therapeutics currently has more cash than debt on its balance sheet, offering financial flexibility as it progresses towards regulatory milestones.

In this update, Dyne Therapeutics provided a larger pooled analysis of patients from the MAD portion of the ACHIEVE study, as well as the baseline video hand opening time in the 71-patient registrational expansion cohort for the first time. The trial has drawn attention due to Novartis's Phase 3 HARBOR trial for del-desiran in DM1, which failed to meet its primary endpoint.

Analysts have responded to these developments with a range of opinions. Jefferies reaffirmed a Buy rating, setting a $50.00 price target, while Piper Sandler maintained an Overweight rating with a $47.00 price target. RBC Capital lowered its price target for Dyne Therapeutics to $30 from $35, noting differences between Dyne's approach and Novartis's recent trial results.

Raymond James also adjusted its price target to $37 from $40, but maintained a Strong Buy rating, alerting investors to potential risks in Dyne's DM1 trial after Novartis's announcement. Stifel noted that Dyne might face additional pressure following Novartis's Phase 3 trial failure. These mixed signals from analysts highlight both the potential and uncertainties surrounding Dyne Therapeutics' current and future prospects.